Skip to main content
. 2017 Oct 4;13(11):1969–1980. doi: 10.1080/15548627.2017.1371393

Figure 6.

Figure 6.

The clearance of overexpressed APP and SNCA by Cory was greatly diminished through the inhibition of MAP2K2 or PLK1. (A) U0126 inhibits the phosphorylation and kinase activity of MAP2K2. (B) BI2356 reduces the PLK1 activity. (C) The changes in LC3B-II and SQSTM1 treated with Cory, after the inhibition of MAP2K2 or PLK1. (D) Quantifications of the SQSTM1:ACTB ratio. (E) Quantifications of the LC3B-II:ACTB ratio. (F) The clearance of FI-APP by Cory, after the inhibition of MAP2K2 or PLK1. (G) Quantifications of the FI-APP:ACTB ratio. (H) The clearance of mutant SNCA by Cory, after the inhibition of MAP2K2 or PLK1. (I) Quantifications of the SNCA:ACTB ratio. **p < 0.01; ***p < 0.001.